Chimerix to Present at Jefferies Global Healthcare Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a corporate overview at the Jefferies Healthcare Conference on June 8, 2022, at 3:30 p.m. in New York City. The presentation will highlight Chimerix's mission to develop medicines to improve and extend the lives of patients with serious diseases. A live audio webcast of the presentation will be accessible on the Investor Relations section of Chimerix’s website and archived for 90 days.

Chimerix's leading clinical program, ONC201, targets H3 K27M-mutant glioma.

DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 p.m. in New York City.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACT:

Investor Relations:
Michelle LaSpaluto
(919) 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
Will@sternir.com
212-362-1200

FAQ

What is the date and time of Chimerix's presentation at the Jefferies Healthcare Conference?

Chimerix's presentation at the Jefferies Healthcare Conference is scheduled for June 8, 2022, at 3:30 p.m.

Where can I watch the Chimerix presentation live?

The live audio webcast of the Chimerix presentation can be found on the Investor Relations section of their website.

What is Chimerix's mission?

Chimerix aims to develop medicines that significantly improve and extend the lives of patients facing deadly diseases.

What is the focus of Chimerix's clinical-stage program ONC201?

ONC201 is being developed for H3 K27M-mutant glioma.

How long will the Chimerix presentation be available for viewing?

The presentation will be archived on the Chimerix website for approximately 90 days.

Who is the CEO of Chimerix?

The CEO of Chimerix is Mike Sherman.